WKBW1h
'It's very tough': Insurance dispute leaves West Seneca toddler without coverage for life-saving treatment
Sophia Watson is in urgent need of life-saving treatment for a tumor, but an insurance dispute has left her family without coverage.
CURE7d
Tafinlar/Mekinist Combo is Safe, Effective in Patients With Glioma
Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...
Precision Medicine Online14d
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
Nasdaq14d
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago.
Zacks Investment Research on MSN14d
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago.